Last updated: May 4, 2026
What is RECARBRIO and what approvals define the current market baseline?
RECARBRIO is an IV combination antibacterial. The marketed regimen is imipenem/cilastatin plus relebactam. The drug is indicated in the U.S. for treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), and in the EU for similar serious bacterial infection uses subject to local SmPC language.
Key commercial anchors:
- U.S. launch: RECARBRIO is already commercially available (see FDA product information via Drugs@FDA and labeling references in [1]-[2]).
- Regulatory labeling: Indication scope and dosing are set by the approved label (see prescribing information in [2]).
Which clinical trials define the next cycle of evidence for RECARBRIO?
RECARBRIO’s clinical development is built around (1) registration-grade efficacy/safety in cUTI/cIAI and (2) additional studies that expand patient populations, endpoints, or comparator positioning. Trial activity is tracked primarily in:
- ClinicalTrials.gov registry (trial status, study design, enrollment, and completion dates) [3].
- Regulatory review and label-referenced pivotal studies (for endpoint definitions and subgroup populations) [1]-[2].
Clinical-trial evidence structure (registration to post-approval):
- Pivotal phase: randomized trials in cUTI and cIAI with microbiological and clinical endpoints consistent with FDA expectations for these indications (pivotal evidence is reflected in label sections and FDA review materials) [1]-[2].
- Post-approval and lifecycle: ongoing or completed studies that test use in additional clinical settings, evaluate safety in broader populations, or compare against standard-of-care antibiotics, with outcomes that can support label expansions depending on regulatory strategy (status and timestamps are in ClinicalTrials.gov) [3].
Trial register status
ClinicalTrials.gov is the authoritative feed for trial timing and status. At present, RECARBRIO trial entries and their statuses can be used to map:
- study start years
- primary completion years
- expected results posting
- and whether trials are completed, recruiting, active not recruiting, or terminated [3].
What are the latest clinical-trial milestones that move investment/reimbursement decisions?
The milestones that matter for RECARBRIO business planning are those that change:
- approved indication language,
- label dosing or duration that affects utilization, or
- the perceived defensibility versus carbapenem alternatives in hospital antimicrobial stewardship.
The latest milestone set is defined by ClinicalTrials.gov updates (trial status and result postings) and by any label revisions tied to new evidence (label change logs in FDA labeling and associated review history) [1]-[3].
Milestones mapping (evidence-to-impact)
- If a trial posts results that strengthen efficacy in a new subgroup** (for example, resistant Gram-negative burden, specific baseline risk classes), the impact is most likely to show up in guideline adoption and formulary review cycles.
- If a trial expands the population (age, renal impairment, polymicrobial baseline risk, or special infection sites), the impact is most likely to show up in usage breadth and physician comfort with empiric decisions.
This milestones mapping requires the exact ClinicalTrials.gov entry list and result posting dates for RECARBRIO; those are published as part of the registry record and are the proper basis for “latest” claims [3].
What does the current competitive landscape look like in cUTI/cIAI?
RECARBRIO competes within a crowded hospital IV antibacterial segment dominated by:
- carbapenems and carbapenem combinations,
- cephalosporin-beta-lactamase inhibitor strategies,
- polymyxin-based or newer Gram-negative directed options depending on resistance patterns,
- and newer agents in hospital stewardship programs.
The competitive question for RECARBRIO is not only whether it works, but whether clinicians prefer it for:
- suspected resistant Gram-negative infections where stewardship aims to reduce carbapenem exposure,
- organisms where beta-lactamase inhibition shifts failure modes, and
- empiric coverage decision windows in ER and inpatient settings.
Market access turns on:
- formulary placement,
- IV workflow fit and dosing simplicity,
- stewardship protocols that reference published susceptibility/efficacy evidence,
- and payer contracting versus branded alternatives.
How large is the addressable market and what adoption constraints matter?
The addressable market for RECARBRIO is principally driven by U.S. and EU hospitalized cUTI/cIAI patient volumes and the share treated with IV broad-spectrum regimens.
Adoption constraints that shape actual revenue take rate:
- restricted formulary positions under stewardship programs,
- infection-control policies around carbapenem-sparing,
- microbiology availability and rapid diagnostics adoption,
- and payer prior authorization requirements where they exist.
Commercial reality in hospital antibiotics also depends on:
- length of inpatient stay,
- severity distribution (ICU share),
- and antibiotic de-escalation practice, which can reduce exposure days.
What is the market projection for RECARBRIO over the next 5 years?
A credible projection requires three inputs that must come from sourced baseline numbers: (1) the revenue run-rate in the most recent fiscal year, (2) updated U.S. and EU prescribing penetration indicators, and (3) planned label expansions or competitive shocks. Those inputs are not provided in the supplied request, and producing a numeric forecast without those sourced baselines would require inventing missing data.
Under the available constraint set, the only compliant market projection is the evidence-based directional framework tied to:
- approved indications and label restrictions [2],
- trial pipeline timing and likelihood of label expansion support [3],
- and competitive substitution logic within cUTI/cIAI hospitalization [1]-[3].
A projection can therefore be expressed only as a scenario logic tied to regulatory and clinical milestones, not as a hard dollar forecast, unless sourced revenue baselines are provided from primary market data.
Scenario-based outlook (directional)
Base case (label remains stable; incremental growth via penetration)
- Growth is driven by incremental formulary adoption and increased IV utilization share within stewardship protocols.
- Clinical differentiators remain those established in the label and pivotal evidence.
Basis: the approved label and its indication scope [2], plus trial status that does not indicate a near-term label expansion pathway [3].
Upside case (pipeline evidence supports expanded use or stronger stewardship positioning)
- RECARBRIO gains broader positioning if trial results support additional populations or stronger resistance subgroups.
- Upside typically appears as improved formulary placement and payer contracting.
Basis: ClinicalTrials.gov for result postings and status changes that can map to label expansion potential [3].
Downside case (competitive substitution or stewardship shifts away)
- Hospitals adjust empiric pathways and formulary preferences based on competitor outcomes or changing resistance prevalence.
- Downside also occurs if clinical evidence does not translate into added penetration beyond the existing label.
Basis: label-defined indications [2] and trial timelines that may reduce pipeline urgency if studies do not yield additional claims [3].
What should investors and operators watch in the next 12 to 18 months?
Operational watch-items tied to measurable signals:
- ClinicalTrials.gov status transitions for RECARBRIO studies: recruiting to active, completion dates, and result postings [3].
- Any label update triggers (FDA labeling and regulatory communications) that change dosing duration, eligibility, or patient selection criteria [1]-[2].
- Evidence publication cadence of trial endpoints that align with stewardship decision-making (Gram-negative coverage, microbiological eradication, and clinical cure endpoints) as reflected in label language and associated studies [1]-[2].
Key Takeaways
- RECARBRIO’s current market baseline is anchored to its approved IV indications in cUTI and cIAI and its label-defined dosing and patient eligibility [2].
- The next business-cycle catalyst is trial status and result postings on ClinicalTrials.gov, which are the authoritative record for pipeline timing [3].
- A numeric 5-year revenue projection cannot be produced without sourced baseline revenue and uptake metrics; compliant outlook is therefore scenario-based and anchored to label stability and pipeline evidence timing [2]-[3].
- Near-term decision-making should focus on registry milestones and any label revisions tied to new evidence [1]-[3].
FAQs
1) What is RECARBRIO’s active drug combination?
Imipenem/cilastatin plus relebactam in an IV regimen [2].
2) What infections is RECARBRIO approved to treat?
In the U.S., it is approved for complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) per the approved prescribing information [2].
3) Where are RECARBRIO clinical trial statuses updated?
ClinicalTrials.gov lists study status, dates, and postings tied to RECARBRIO trials [3].
4) What is the fastest signal for potential label expansion?
A completed study with posted results on ClinicalTrials.gov that can support additional claims, followed by any FDA/EU label update activity [3]-[1].
5) What drives formulary adoption for hospital antibiotics like RECARBRIO?
Hospital stewardship policies, microbiology fit to the expected resistant pathogen mix, and payer or formulary decisions that align with label language and published endpoints [2]-[3].
References
[1] U.S. Food and Drug Administration. FDA label and review information for RECARBRIO (imipenem and cilastatin; relebactam). Drugs@FDA.
[2] U.S. Food and Drug Administration. RECARBRIO (imipenem and cilastatin; relebactam) prescribing information.
[3] U.S. National Library of Medicine. ClinicalTrials.gov: RECARBRIO (imipenem/relebactam-related) trials registry entries and status updates.
